The Effects of Metreleptin in Congenital Leptin Deficiency

Plain-language summary

This study looks at the effects of a medication called Metreleptin in people with congenital leptin deficiency. Adults aged 18 and older with a diagnosis of congenital leptin deficiency could take part. It was carried out as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Northwestern University

Intervention

Metreleptin

Start date

6/20/2019

Estimated completion

8/13/2021

Countries

United States

Related genes

Locations

• Chicago, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of congenital leptin deficiency
* Age 18 years or older
* Must agree to use contraception for the duration of treatment with metreleptin and for 6 months post-treatment completion.

Exclusion Criteria:

* Presence of a clinically significant medical condition that could significantly affect the risk/benefit ratio for metreleptin treatment, as judged by the PI
* Known allergies to E. coli-derived proteins or hypersensitivity to any component of metreleptin treatment